ADVANCE(R) II MODULAR TIBIAL BASE W/SCREWHOLES, Knee Tibial Base, REF KTTIHA11, SIZE 1+; SURFACE...
FDA Device Recall #Z-2694-2016 — Class I — June 21, 2016
Recall Summary
| Recall Number | Z-2694-2016 |
| Classification | Class I — Serious risk |
| Date Initiated | June 21, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | MicroPort Orthopedics Inc. |
| Location | Arlington, TN |
| Product Type | Devices |
| Quantity | 36 units |
Product Description
ADVANCE(R) II MODULAR TIBIAL BASE W/SCREWHOLES, Knee Tibial Base, REF KTTIHA11, SIZE 1+; SURFACE POROUS, HA COATED; FIT CEMENTLESS; USE W/ SIZE 1 FEMUR & SIZE 1 TIBIAL INSERT; CONTENTS, 1 EACH, STERILE R, Rx ONLY, MicroPort Knee Systems Total Knee Systems MicroPort Total Knee Systems are indicated for use in knee arthroplasty in skeletally mature patients with the following conditions: 1) noninflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis; 2) inflammatory degenerative joint disease including rheumatoid arthritis; 3) correction of functional deformity; 4) revision procedures where other treatments or devices have failed; and treatment of fractures that are unmanageable using other techniques.
Reason for Recall
ADVANCE(R) HA Coated tibial bases are being recalled due to a higher than expected revision rate as a result of component loosening.
Distribution Pattern
Worldwide Distribution only to Australia, Austria, France, Italy, Spain, and United Kingdom
Lot / Code Information
all codes
Other Recalls from MicroPort Orthopedics Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1133-2026 | Class II | Brand Name: MicroPort Product Name: HIPTURN FE... | Dec 19, 2025 |
| Z-0699-2025 | Class II | EVOLUTION MP FEMORAL COMPONENT CS/CR POROUS SIZ... | Oct 29, 2024 |
| Z-2244-2024 | Class II | EVOLUTION¿ MP Femoral CS/CR Non-Porous Non-p... | May 3, 2024 |
| Z-0275-2023 | Class II | EVOLUTION MP Tibial Bases, Size 2+ LEFT, REF ET... | Oct 28, 2022 |
| Z-0276-2023 | Class II | EVOLUTION MP Tibial Bases, Size 7 LEFT, REF ETP... | Oct 28, 2022 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.